

CURRICULUM VITAE

Name: **MATTHIAS DROSTEN**
Present position: Investigator
Work address: Centro Nacional de Investigaciones Oncológicas
Melchor Fernández Almagro 3
28029 Madrid, Spain
E-Mail: mdrosten@cnio.es
ORCID ID: 0000-0002-3205-456X
LinkedIn: www.linkedin.com/in/matthias-drosten-70055a9a

Research appointments

2008 - present	Investigator (Staff Scientist), Experimental Oncology Group, Spanish National Cancer Centre (CNIO), Madrid, Spain
2020	Científico titular at CSIC (in expectation)
2004 - 2008	Postdoctoral fellow, Experimental Oncology Group, Spanish National Cancer Centre (CNIO), Madrid, Spain (Group leader: Dr. Mariano Barbacid)

Academic formation

1999 – 2003	Ph.D. (Dr. rer. nat.) , University of Essen Medical School, Department of Molecular Biology (IMB), Essen, Germany (Supervisor: Prof. Dr. Dr. Brigitte M. Pützer)
1993 – 1999	Degree in Biology (Dipl.-Biol.) , Ruhr-University of Bochum, Germany

Selected publications

1. Sanclemente M, Nieto P, García-Alonso S, Fernández-García F, Esteban-Burgos L, Guerra C, **Drosten M**, Caleiras E, Martínez-Torrecuadrada J, Santamaría D, Musteanu M, Barbacid M (2021) RAF1 kinase activity is dispensable for KRAS/p53 mutant lung tumor progression. *Cancer Cell*, 39 (3), 294-296.
2. Lechuga CG, Salmón M, Paniagua G, Guerra C, Barbacid M, **Drosten M** (2021) RASless MEFs as a tool to study RAS-dependent and RAS-independent functions. *Methods Mol Biol*, *in press*.
3. Esteban-Burgos L, Wang H, Nieto P, Zheng J, Blanco-Aparicio C, Varela C, Gómez-López G, Fernández-García F, Sanclemente M, Guerra C, **Drosten M**, Galán J, Caleiras E, Martínez-Torrecuadrada J, Fajas L, Peng SB, Santamaría D, Musteanu M, Barbacid M (2020) Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in Kras/p53 mutant lung adenocarcinomas. *Proc Natl Acad Sci USA*, 117 (39), 24415-24426.
4. **Drosten M***, Barbacid M* (2020). Targeting the MAPK pathway in KRAS-driven tumors. *Cancer Cell*, 37 (4), 543-550. [* corresponding author]
5. Vitos-Faleato J, Real SM, Gutierrez-Prat N, Villanueva A, Llonch E, **Drosten M**, Barbacid M, Nebreda AR (2020). Requirement for epithelial p38 α in KRAS-driven lung tumor progression. *Proc Natl Acad Sci USA*, 117 (5), 2588-2596.
6. Blasco MT, Navas C, Martín-Serrano G, Graña-Castro O, Lechuga CG, Martín-Díaz L, Djurec M, Li J, Morales-Cacho L, Esteban-Burgos L, Perales-Patón J, Bousquet-Mur E, Castellano E, Jacob HKC, Cabras L, Musteanu M, **Drosten M**, Ortega S, Mulero F, Sainz Jr B, Dusetti N, Iovanna J, Sánchez-Bueno F, Hidalgo M, Khiabanian H, Rabadán R, Al-Shahrour F, Guerra C, Barbacid M (2019). Complete regression of advanced pancreatic ductal adenocarcinomas upon combined inhibition of EGFR and c-RAF. *Cancer Cell*, 35 (4), 573-587.

CURRICULUM VITAE

7. Mayor-Ruiz C, Olbrich T, **Drosten M**, Lecona E, Vega-Sendino M, Ortega S, Dominguez O, Barbacid M, Ruiz S, Fernandez-Capetillo O (2018). ERF deletion rescues RAS deficiency in mouse embryonic stem cells. *Genes Dev*, 32 (7-8), 568-576.
8. Gao Y, Chang MT, McKay D, Na N, Zhou B, Yaeger RD, Torres NM, Muniz K, **Drosten M**, Barbacid M, Caponigro G, Stuart D, Moebitz H, Solit DB, Abdel-Wahab OI, Taylor BS, Yao Z, Rosen N (2018). Allele-specific mechanisms of activation of MEK1 mutants determine their properties. *Cancer Discov*, 8 (5), 648-661.
9. Simón-Carrasco L, Jiménez G*, Barbacid M, **Drosten M*** (2018). The Capicua tumor suppressor: a gatekeeper of Ras signaling in development and cancer. *Cell Cycle* 17 (6), 702-711. [* corresponding author]
10. Sanclemente M, Francoz S, Esteban-Burgos L, Bousquet-Mur E, Lopez-Casas PP, Hidalgo M, Guerra C, **Drosten M**, Musteanu M, Barbacid M (2018). c-Raf ablation induces regression of advanced Kras/Trp53 mutant lung adenocarcinomas by a mechanism independent of MAPK signaling. *Cancer Cell* 33 (2), 217-228.
11. **Drosten M***, Guerra C*, Barbacid M* (2017). Genetically engineered mouse models of K-Ras-driven lung and pancreatic tumors: validation of therapeutic targets. *Cold Spring Harb Perspect Med*, a031542. [* corresponding author]
12. Simón-Carrasco L, Graña O, Salmón M, Jacob HKC, Gutierrez A, Jiménez G, **Drosten M***, Barbacid M* (2017). Inactivation of Capicua in adult mice causes T cell lymphoblastic lymphoma. *Genes Dev* 31 (14), 1456-1468. [*senior author]
13. Yao Z, Yaeger R, Rodrik-Outmezguine VS, Tao A, Torres NM, Chang MT, **Drosten M**, Zhao H, Cecchi F, Hembrough T, Michels J, Baumert H, Miles L, Campbell NM, de Stanchina E, Solit DB, Barbacid M, Taylor BS, Rosen N (2017). Tumors with class 3 BRAF mutants are RAS dependent and sensitive to its inhibition. *Nature* 548 (7666), 234-238.
14. Forés M, Simón-Carrasco L, Ajuria L, Samper N, González-Crespo S, **Drosten M**, Barbacid M, Jiménez G (2017). A new mode of DNA binding distinguishes Capicua from other HMG-box factors and explains its mutation patterns in cancer. *PLoS Genet* 13 (3), 31006622.
15. **Drosten M***, Simón-Carrasco L, Hernández-Porras I, Lechuga CG, Blasco MT, Jacob HKC, Fabbiano S, Potenza N, Bustelo XR, Guerra C, Barbacid M* (2017). H-Ras and K-Ras oncoproteins induce different tumor spectra when driven by the same regulatory sequences. *Cancer Res* 77 (3), 707-718. [* corresponding author]
16. **Drosten M***, Sum EYM, Lechuga CG, Simón-Carrasco L, Jacob HKC, Garcia-Medina R, Huang S, Beijersbergen RL, Bernards R, Barbacid M* (2014). Loss of p53 induces cell proliferation via Ras-independent activation of the Raf/Mek/Erk signaling pathway. *Proc Natl Acad Sci USA* 111 (42), 15155-15600. [* corresponding author]
17. **Drosten M***, Lechuga CG, Barbacid M* (2014). Ras signaling is essential for skin development. *Oncogene* 33 (22), 2857-2865. [* corresponding author]
18. **Drosten M**, Dhawahir A, Sum EYM, Urosevic J, Lechuga CG, Esteban LM, Castellano E, Guerra C, Santos E, Barbacid M (2010). Genetic analysis of Ras signaling pathways in cell proliferation, migration and survival. *EMBO J* 29 (6), 1091-1104.